Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:15:28.785Z.
Calculation as of: 2026-10-06T14:15:28.785Z.
Quote observation: 2026-10-06T14:15:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5d81df243028a463df18dadfb6b81954a95dec5b5738e9798e17a16434fd93e0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Acumen Pharmaceuticals, Inc.
Market Cap
$146.22M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.84M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$153.31M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$138.28M
Price/FCF Ratio
1.10
TTM Avg
4.90
3Y Avg
4.90
5Y Avg
4.90
Market Cap
$138.62M
Price/FCF Ratio
182.40
TTM Avg
111.34
3Y Avg
100.72
5Y Avg
72.71
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $146.22M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $147.84M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $144.85M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $153.31M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $152.20M | N/A | 55.06 | 55.06 | 55.06 |
| LifeMD, Inc. (LFMDP)vs › | $142.72M | N/A | 177.92 | 1258.54 | 1258.54 |
| Fortress Biotech, Inc. (FBIOP)vs › | $138.28M | 1.10 | 4.90 | 4.90 | 4.90 |
| Alpha Cognition Inc (ACOG)vs › | $141.33M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $138.62M | 182.40 | 111.34 | 100.72 | 72.71 |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
